Actively Recruiting
Observational Study of Indolent Systemic Mastocytosis Patient Characteristics and Treatment Management Including Avapritinib
Led by Blueprint Medicines Corporation · Updated on 2026-09-04
150
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 4, non-interventional, observational study to collect detailed information about people with indolent systemic mastocytosis ISM. The study aims to understand the clinical features, outcomes, and how ISM is managed in real-world settings. It focuses on describing participants demographics and clinical characteristics, including episodes of anaphylaxis and bone-related issues. Quality of life and disease control will be measured through questionnaires completed by participants. Participants in this study include those currently being treated or planning to be treated for ISM, including treatment with symptom-directed therapies and the drug avapritinib. The study does not involve administering any treatments but observes and records how ISM is managed in everyday clinical practice over time. The observation period extends up to 61 months from baseline assessments. During the study, participants will provide information on their demographics and clinical status at baseline and will complete patient-reported outcome questionnaires up to month 61. Researchers will also monitor changes in blood markers such as serum KIT D816V variant allele frequency and serum tryptase levels. The study will track changes in symptom-directed therapies as well. Participation lasts for several years, with ongoing data collection to better understand ISM in a real-world context.
CONDITIONS
Brief Title
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Research Team
B
Blueprint Medicines
B
Blueprint Medicines, EU Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here